Universe Pharmaceuticals (UPC) Other Accumulated Expenses (2021 - 2025)

Universe Pharmaceuticals has disclosed Other Accumulated Expenses across 5 years of filings, most recently posting $54.7 million for Q3 2025.

• Other Accumulated Expenses for Q3 2025 came in at $54.7 million, down 62.88% year-over-year; the trailing twelve-month figure through Sep 2025 was $54.7 million (down 62.88% YoY), and the FY2025 annual result was $54.7 million, down 62.88% from the prior year.
• Other Accumulated Expenses came in at $54.7 million for Q3 2025 at Universe Pharmaceuticals, down from $147.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $147.4 million in Q3 2024 to a low of $52263.0 in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $444319.0 (2021), against an average of $40.6 million.
• Across the five-year window, Other Accumulated Expenses slumped 88.24% in 2022 and jumped 112404.1% in 2024, its largest moves.
• Universe Pharmaceuticals' Other Accumulated Expenses stood at $444319.0 in 2021, then plunged by 88.24% to $52263.0 in 2022, then surged by 150.74% to $131045.0 in 2023, then surged by 112404.1% to $147.4 million in 2024, then sank by 62.88% to $54.7 million in 2025.
• The last three Other Accumulated Expenses figures came in at $54.7 million (Q3 2025), $147.4 million (Q3 2024), and $131045.0 (Q3 2023), per Business Quant data.